birb 796 has been researched along with paclitaxel in 1 studies
Studies (birb 796) | Trials (birb 796) | Recent Studies (post-2010) (birb 796) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
---|---|---|---|---|---|
137 | 5 | 80 | 31,874 | 5,729 | 15,395 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, XG; Chen, ZS; Fang, Y; Fu, LW; He, D; Liang, YJ; Qiu, HJ; Singh, S; Talele, TT; Wang, XK; Zhang, GQ; Zhao, XQ | 1 |
1 other study(ies) available for birb 796 and paclitaxel
Article | Year |
---|---|
BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; HEK293 Cells; HL-60 Cells; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Naphthalenes; Neoplasms; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Protein Kinase Inhibitors; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2013 |